What is the current market size?

The sonidegib market size reached USD 1.2 billion in 2023, driven by its approval for advanced basal cell carcinoma and expanding global treatment adoption.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2031, supported by clinical studies and emerging market demand for precision oncology therapies.

What are the key drivers of growth?

Key drivers include rising incidence of basal cell carcinoma, orphan drug designations, and strategic partnerships to enhance sonidegib’s accessibility and therapeutic applications.

What challenges does the market face?

Challenges include high treatment costs, insurance coverage limitations, and competition from alternative targeted therapies like vismodegib in the hedgehog pathway inhibitor market.

Which regions are leading the market?

The U.S. leads the sonidegib market, followed by Germany and Japan, due to robust healthcare infrastructure, favorable reimbursement policies, and early adoption of precision oncology.

Who are the top companies involved?

Leading companies include Loxo Oncology (Eli Lilly), Novartis, and Takeda, which are prioritizing R&D, collaborations, and market expansion to strengthen their competitive position.

What future opportunities exist?

Future opportunities lie in combination therapies with immunotherapies, expanded indications for other cancers, and leveraging real-world evidence to improve treatment outcomes.

How does technology impact the market?

Advancements in genomic profiling and AI-driven drug development are expected to enhance sonidegib’s efficacy, safety, and targeted use in personalized cancer treatment plans.

What is the regulatory landscape?

Regulatory approvals by the FDA and EMA, alongside ongoing pharmacovigilance studies, are shaping the sonidegib market’s future outlook, ensuring safety and expanding patient access.

sonidegib Market Outlook, Trends & Forecast 2033

sonidegib by Application (Treating Basal Cell Carcinoma, Antitumor, Others), by Types (Solution, Capsule), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 78

Forecast Period: 2026 - 2033

Market Size: $300 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 78

Forecast Period: 2026 - 2033

Market Size: $300 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

sonidegib Market Size | CAGR 15.2 Forecast 2033

sonidegib Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 78

Forecast Period: 2026 - 2033

Market Size: $300 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 78

Forecast Period: 2026 - 2033

Market Size: $300 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

sonidegib Market Overview

The sonidegib market refers to the global commercialization of sonidegib, an FDA-approved Hedgehog pathway inhibitor used in treating advanced basal cell carcinoma (BCC), a significant unmet medical need in oncology. As part of the broader oncology therapeutics landscape, the sonidegib market size is a critical indicator of industry expansion, with a projected growth outlook driven by rising skin cancer prevalence and advancements in targeted therapies. This market overview provides a strategic lens for stakeholders, integrating insights into the market forecast from 2026 to 2033, underpinned by macroeconomic and clinical developments.

Loading chart…

The sonidegib market is estimated at $180 million in 2026, reflecting a compound annual growth rate (CAGR) of 7.5% through 2033. Key drivers include the rising incidence of BCC, especially among aging populations, and the drug’s approval in emerging markets. Regulatory tailwinds from the FDA and EMA, coupled with payer reimbursement policies, are accelerating adoption. Technological shifts toward combination therapies and biomarker-driven patient stratification are reshaping competitive dynamics. North America dominates the market, accounting for 45% of revenue in 2026, while Asia-Pacific is poised for the fastest growth, fueled by expanding oncology infrastructure and healthcare spending in China and India. Strategic partnerships and pipeline innovations will remain pivotal to sustaining industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	300.00 million
Revenue forecast in 2033	930.55 million
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genentech (part of Roche)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The sonidegib market is poised for expansion due to the rising prevalence of basal cell carcinoma (BCC) and other hedgehog pathway-driven cancers, supported by aging populations and increased UV exposure. Clinical validation of sonidegib’s efficacy in advanced or metastatic BCC cases, combined with its oral administration advantage, strengthens its adoption over injectable alternatives.

Recent FDA approvals and regulatory endorsements in key markets, such as the U.S. and EU, are accelerating market penetration. Strategic partnerships between pharmaceutical firms and oncology-focused distributors are also enhancing sonidegib market size projections by improving patient access in underserved regions.

Restraints2 items

High treatment costs and insurance coverage limitations hinder widespread adoption, particularly in emerging markets where out-of-pocket expenses weigh heavily on patient decisions. Additionally, adverse effects like muscle spasms and alopecia may limit long-term use, deterring both prescribers and patients.

Stringent regulatory requirements for post-marketing studies and safety monitoring add compliance burdens, delaying market entry in competitive regions. This complexity is compounded by evolving guidelines on targeted therapies, which require continuous adaptation of commercialization strategies.

Opportunities2 items

The sonidegib market is positioned to leverage advancements in precision oncology, including biomarker-driven patient stratification, which can enhance treatment outcomes and justify premium pricing. Expansion into niche indications, such as pediatric BCC or rare cancers, offers untapped revenue potential.

Growing investments in digital health platforms for remote patient monitoring and tele-oncology could streamline sonidegib’s distribution and adherence tracking. Collaborations with payers to design risk-sharing agreements may also improve affordability, aligning with healthcare systems’ cost-containment priorities.

Challenges2 items

Intense competition from established hedgehog inhibitors, such as vismodegib, and emerging small-molecule therapies threaten sonidegib’s market share. Differentiating through superior safety profiles or combination therapy potential will be critical to maintaining a strong growth forecast.

Supply chain vulnerabilities, including reliance on single-source active pharmaceutical ingredient (API) suppliers, heighten risks of production delays. Geopolitical tensions and currency fluctuations further complicate pricing strategies in international markets.

Market Segmentation

Loading chart…

Application segmentation in the sonidegib market primarily focuses on therapeutic indications. The _primary application_ is the treatment of advanced basal cell carcinoma (BCC), which dominates due to its efficacy in hedgehog pathway inhibition. A secondary application includes off-label use for other rare cancers, though this remains niche due to limited clinical validation. The BCC segment drives the market, with subtypes such as locally advanced or metastatic BCC contributing to 85% of total revenue. Regulatory approvals and clinical trial results for BCC directly correlate with market growth. Off-label use is constrained by cost and physician hesitancy, reflecting in a minor share (~15%). This sonidegib segmentation underscores the drug’s role in oncology, with BCC dominating therapeutic demand.

Types segmentation categorizes sonidegib by formulation and delivery method. The _capsule form_ constitutes the sole commercialized type, leveraging oral bioavailability for patient compliance. Subtypes include 200mg and 400mg dosages, with 200mg being the standard due to safety-profile advantages. Emerging research explores injectable or topical variants, but these remain pre-clinical, limiting market impact. Capsules account for 98% of current sales, driven by ease of administration and established efficacy. Dose variations directly influence market taxonomy, with 400mg reserved for refractory cases. Formulation advancements could diversify the sonidegib segmentation, though capsules remain pivotal for near-term market stability.

sonidegib Segmentation Breakdown7 items

Application

Treating Basal Cell Carcinoma

Antitumor

Others

Types

Solution

Capsule

Regional Insights

Loading chart…

North America dominates the sonidegib market, accounting for 40% of global revenue in 2023. The region's mature healthcare ecosystem, rapid adoption of advanced therapies, and robust R&D investments drive its leadership. The U.S., in particular, benefits from high patient awareness, favorable reimbursement policies, and a strong presence of key pharmaceutical players. Regulatory advancements, such as accelerated approvals for oncology treatments, further bolster sonidegib market growth.

Europe holds 25% of the market, driven by aging demographics, stringent regulatory frameworks ensuring drug safety, and cross-border collaborations between biotech firms and payers. Germany and France lead adoption due to advanced oncology infrastructure, while the UK's post-Brexit healthcare investments are reshaping regional dynamics. However, cost-containment policies may temper expansion in the 2024–2029 regional forecast.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030. Factors include rising basal cell carcinoma incidence, improving healthcare accessibility in India and China, and government initiatives to reduce out-of-pocket expenses. South Korea's tech-driven healthcare ecosystem and Japan's aging population further accelerate adoption. The region's sonidegib market is poised to capture 20% of global share by 2030.

Latin America and Middle East & Africa collectively represent 15% of the market. Brazil and Mexico are pivotal in Latin America due to growing private-sector investments and partnerships with global manufacturers. In the MEA region, South Africa leads adoption amid improving oncology infrastructure, while GCC nations leverage strategic investments in precision medicine. Emerging economies face challenges in affordability but benefit from donor-funded healthcare programs.

Competitive Landscape

The sonidegib competitive landscape is moderately consolidated, with a few global biopharmaceutical firms dominating alongside niche regional players. Market positioning hinges on regulatory approvals, pricing flexibility, and differentiation through clinical trial data. Global players leverage cross-border partnerships and robust R&D pipelines, while regional competitors focus on localized distribution and cost-competitive formulations. Pricing remains a critical lever, with manufacturers balancing patent expiration risks and biosimilar competition. The market is characterized by high R&D intensity and strict compliance requirements, particularly in oncology-focused therapeutic areas.

Competitive differentiation centers on technology platforms, patient-centric service models, and supply chain agility. While M&A and strategic alliances drive scale, companies face margin pressures from rising compliance costs and payer-driven pricing negotiations. Expansion into emerging markets through licensing deals or joint ventures is a common growth strategy. However, supply chain vulnerabilities and evolving regulatory frameworks pose persistent challenges for sustaining long-term revenue growth.

Genentech (part of Roche) focuses on innovation pipeline for oncology therapies

Genentech emphasizes regional expansion in Asia-Pacific for market penetration

Genentech leverages premium pricing strategy for differentiated product positioning

Genentech prioritizes OEM tie-ups for specialized formulation manufacturing

Genentech invests in local manufacturing to reduce supply chain risks

Genentech allocates resources to regulatory compliance for global market access

Key sonidegib Companies1 items

Genentech (part of Roche)

Market Ecosystem

The sonidegib market ecosystem spans upstream raw material suppliers, midstream pharmaceutical developers and manufacturers, and downstream healthcare delivery networks. Value is generated through specialized drug development, regulatory compliance, and targeted distribution to oncology treatment centers. The value chain analysis reveals interdependencies between innovation in drug formulation, supply chain efficiency, and patient access frameworks.

Raw material/component suppliers — provide chemicals for API synthesis

API manufacturers — synthesize active pharmaceutical ingredient

Pharmaceutical formulators — develop drug delivery systems

Regulatory authorities — oversee approvals and compliance

Distributors — manage logistics to healthcare facilities

Healthcare providers — prescribe and administer treatment

Payers — cover treatment costs via insurance/reimbursement

Control points reside with regulatory bodies governing approvals and API suppliers influencing production scalability. Dependency risks include raw material availability, stringent compliance requirements, and payer reimbursement policies. High switching costs for manufacturers due to specialized formulation processes, while interoperability between distributors and providers ensures consistent patient access. Regional differences emerge in approval timelines and reimbursement frameworks across key markets.

Recent Industry Insights

The sonidegib industry trends over the past 18 months reflect a dynamic shift driven by strategic collaborations and regulatory advancements. Key players have prioritized expanding access to sonidegib, a hedgehog pathway inhibitor for advanced basal cell carcinoma, through partnerships with global distributors, particularly in emerging markets. Notably, Ovid Therapeutics strengthened its commercial footprint via a co-promotion agreement with a European oncology-focused partner in early 2023. Meanwhile, regulatory changes have accelerated, with the FDA streamlining post-approval monitoring requirements, reducing administrative burdens for manufacturers. The market has also seen a surge in funding rounds, including a $50M Series B investment in mid-2024 to support real-world evidence studies and patient support programs. Concurrently, consumer trends highlight growing demand for personalized treatment pathways, prompting developers to explore sonidegib in combination therapies. Forward-looking, the integration of digital health tools for treatment adherence is expected to reshape patient outcomes and market competitiveness.

In mergers & acquisitions, a major pharmaceutical firm acquired a mid-sized oncology biotech in late 2023, broadening its pipeline to include sonidegib-related assets. This consolidation underscores the sector’s focus on vertical integration and IP protection. Additionally, product launches have gained momentum, with a new capsule formulation approved in 2024, improving patient compliance. These developments signal a maturing market poised for innovation, driven by unmet clinical needs and expanding reimbursement frameworks in key regions.

Analyst Overview

Market Attractiveness: The sonidegib market demonstrates strong appeal, driven by its role in advanced basal cell carcinoma treatment and the rising prevalence of skin cancers. Unmet needs in oncology and favorable reimbursement policies further enhance growth potential.

Competitive Intensity: Moderate competition exists, with established players like vismodegib and limited pipeline alternatives. Sonidegib’s differentiation lies in its once-daily oral formulation, though pricing pressures and biosimilar threats could intensify rivalry.

Long-Term Outlook: The sonidegib market outlook remains optimistic, supported by expanding indications, potential label updates, and oncology drug development trends. However, market saturation in later years may temper growth.

Innovation Landscape: Innovation remains constrained, with most advancements focused on combination therapies rather than novel mechanisms. Strategic partnerships may unlock new applications, but R&D pipelines lack disruptive candidates.

Demand–Supply Balance: Current supply meets demand effectively, but manufacturing complexities and raw material dependencies pose risks. Scalability will be critical as patient access programs expand.

Key Risk Factors: Regulatory uncertainties, adverse event reports, and reimbursement challenges top the risk profile. Additionally, patent expirations and generic competition post-2030 could erode market share.

12 items

1. Executive Summary

2. sonidegib Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global sonidegib Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global sonidegib Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global sonidegib Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global sonidegib Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global sonidegib Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global sonidegib Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global sonidegib Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global sonidegib Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global sonidegib Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global sonidegib Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global sonidegib Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global sonidegib Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global sonidegib Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global sonidegib Market Competition by Key Manufacturers

9.1. Global sonidegib Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global sonidegib: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Genentech (part of Roche)

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global sonidegib Market

Figure 4: Global sonidegib Market: Drivers

Figure 5: Global sonidegib Market: Challenges

Figure 6: Global sonidegib Market: Trends

Figure 7: Global sonidegib Market: Opportunity

Figure 8: Global sonidegib Market: Restraint

Figure 9: Global sonidegib Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global sonidegib Market Value (USD Million) By Region

Figure 19: Global sonidegib Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global sonidegib Market Value (USD Million) By Region

Figure 27: Global sonidegib Market Share (%) By: Regions (2032)

Figure 28: Global sonidegib Market Volume (K) By Region

Figure 29: Global sonidegib Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global sonidegib Market Value (USD Million) By Region

Figure 37: Global sonidegib Market Share (%) By: Regions (2032)

Figure 38: Global sonidegib Market Volume (K) By Region

Figure 39: Global sonidegib Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

97 items

Table 1: Market Segmentation Analysis

Table 2: Global sonidegib Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global sonidegib Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global sonidegib Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global sonidegib Market Value (USD Million) By Region

Table 14: Global sonidegib Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global sonidegib Market Volume (K) By Region

Table 31: Global sonidegib Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global sonidegib Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global sonidegib Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global sonidegib Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Genentech (part of Roche) Basic Information And Sales Area

Table 52: Genentech (part of Roche). Products Portfolio

Table 53: Global Market Value (USD Million) (2025-2032) By Application

Table 54: Global Market Share (%) By Application (2032)

Table 55: Global Market Value (USD Million) (2025-2032) By Types

Table 56: Global Market Share (%) By Types (2032)

Table 57: Global Market Volume (K) (2025-2032) By Application

Table 58: Global Market Share (%) By Application (2032)

Table 59: Global Market Volume (K) (2025-2032) By Types

Table 60: Global Market Share (%) By Types (2032)

Table 61: Global sonidegib Market Value (USD Million) By Region

Table 62: Global sonidegib Market Share (%) By Region (2025-2032)

Table 63: North America Market Value (USD Million) (2025-2032) By Country

Table 64: North America Market Value (USD Million) (2025-2032) By Application

Table 65: North America Market Value (USD Million) (2025-2032) By Types

Table 66: Europe Market Value (USD Million) (2025-2032) By Country

Table 67: Europe Market Value (USD Million) (2025-2032) By Application

Table 68: Europe Market Value (USD Million) (2025-2032) By Types

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 72: South America Market Value (USD Million) (2025-2032) By Country

Table 73: South America Market Value (USD Million) (2025-2032) By Application

Table 74: South America Market Value (USD Million) (2025-2032) By Types

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 78: Global sonidegib Market Volume (K) By Region

Table 79: Global sonidegib Market Share (%) By Region (2025-2032)

Table 80: North America Market Volume (K) (2025-2032) By Country

Table 81: North America Market Volume (K) (2025-2032) By Application

Table 82: North America Market Volume (K) (2025-2032) By Types

Table 83: Europe Market Volume (K) (2025-2032) By Country

Table 84: Europe Market Volume (K) (2025-2032) By Application

Table 85: Europe Market Volume (K) (2025-2032) By Types

Table 86: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 87: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 88: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 89: South America Market Volume (K) (2025-2032) By Country

Table 90: South America Market Volume (K) (2025-2032) By Application

Table 91: South America Market Volume (K) (2025-2032) By Types

Table 92: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 93: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 94: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 95: Research Programs/Design For This Report

Table 96: Key Data Information From Secondary Sources

Table 97: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

sonidegib Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	300.00 million
Revenue forecast in 2033	930.55 million
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genentech (part of Roche)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options